Monterey Bay Forum

More and more often, I come across cases of nonsmokers who develop lung cancer. My attention is always drawn to news of this nature because my husband passed away at the age of 51 from brain and lung cancer. He never smoked a day in his life.

Well Online Casino or Online Poker ar good Ways to make Money.

Good one. All the ingredients can be found in the household and its kinda easy to do it. So I may try one of these remedy.

While US courts conduct legal battles over the ethics of stem cell research and Big Pharma shuts down clinical trials citing ‘tighter budgets’, North Americans wait for solid proof of stem cell efficacy for many disease conditions. Health organizations such as the National Cancer Institute issue continual warnings about lack of proof for stem cell therapy. National media shows like CBSs’ 60 Minutes, paid for by their advertisers that include Big Pharma, perform razor-sharp hatchet jobs on those quack clinics doing fake stem cell therapy, but in the process paint every other clinic everywhere doing stem cell research and therapy with the same brush.
In the meantime, medical institutions in other countries plough along with research from trials that not only provide good evidence on the safety of stem cells, but also their efficacy for many disease conditions with autoimmune causes. For example, the current accepted treatment strategies for MS are only known to decrease inflammation but have no effect on repairing material damage to the CNS, effectively reversing the disease. What isn’t yet accepted in the medical community is that stem cell transplantation demonstrates a new approach for supporting restoration of tissue through remyelination. Through multiple clinical trials that have already proceeded to phase III, it has been well-established that mesenchymal stem cells moderate responses of the disease and stimulate repair of the central nervous system. In these studies, adult autologous mesenchymal stem cells have not only been safely administered to MS patients but have proven effective as a potential therapy for MS. Approved Clinical Trials involving small numbers of patients have occurred for the past half decade in medical centers outside of North America. As a result, various medical treatment centers have already derived protocols for extraction, culture, and treatment of MS patients with autologous stem cells. A review of popular medical journals actually reveals a widespread consensus on the efficacy of mesenchymal stem cell transplantation as a therapy for MS patients.
After 18 months of treating MS patients, CCSVI Clinic is well along with its program. “Success means different things to different people, but I’d say we’ve had much more than we could have hoped for when we first started.” says Dr. Avneesh Gupte, Neurosurgeon with CCSVI Clinic. “For the past year we’ve been adding autologous mesenchymal stem cell transplantation to the liberation therapy procedure and that’s when we really started to notice a significant change in patient outcomes”. Autologous Mesenchymal stem cell transplantation (AMSCT) means that the stem cells are taken from the patient’s own body and are cultured prior to transplantation at various times over an extended period. With the patient as the donor, there is no risk of transplantation leading to cancer as opposed to the risks of transplanting embryonic stem cells. AMSCT is now regularly used in North America for the treatment of Hodgkin’s lymphoma and non-Hodgkin’s lymphoma as well as other diseases with remarkable results including cure for many patients. “If it works for some diseases, is safe and well-tolerated by the patient, then why not other diseases? We believe that Multiple Sclerosis can now be added to that list.” says Gupte.
In the past four years Gupte has performed over 1500 autologous stem cell transplantations for many types of neuro-degenerative diseases, including MS, cerebral palsy, ALS, Crohn’s Disease, Huntington’s, and Parkinson’s among others.
For the past year, CCSVI Clinic has not done the ‘liberation therapy’ for MS alone without the combined stem cell transplantation in the same 12-day protocol sequence. “Once we saw how dramatic and long-lasting the outcomes were with the addition of the stem cells, it didn’t make sense to do it any other way.” says Gupte. Most MS patients would agree. Lawrence Vermeersch of Kenora, Canada is convinced that it’s the stem cells that are continuing to make the difference in his recovery. “I’m thinking it will take a year to full recovery, but I’m continuing to improve every day.”
Jessica Davis, diagnosed with MS in 2003, of Somerset, UK agrees: “I have my life back thanks to CCSVI Clinic and it’s the best thing I ever did for myself. They weren’t easy to find but I did my homework.” She continues: “I had to be my own advocate for both liberation therapy and the stem cells because I got no help from my own neurologist. From the day I was diagnosed, my MS was aggressive. I didn’t have much time to take action before I would get to the point where just getting out of the flat would become impossible. I was using a cane and so tired all the time. After the 12 days at CCSVI Clinic, the first thing that cleared up was the head fog and my (incontinence) and the rest has come back over the past six months. I am working again and I consider myself cured.”
“These are typical stories for all types of neuro-degenerative diseases we are treating through CCSVI Clinic. At least with MS we are seeing significant improvement in many patients and I believe this trend of outcomes will continue” says Gupte. “We have also had some significantly positive outcomes with ALS and (cerebral) palsy. With the results we have seen in the past year, I think that the promise of stem cells is coming closer to matching the reality.” For more details visit http://ccsviclinic.ca/

Stem cells are “non-specialized” cells that have the potential to form into other types of specific cells, such as blood, muscles or nerves. They are unlike “differentiated” cells which have already become whatever organ or structure they are in the body. Stem cells are present throughout our body, but more abundant in a fetus.
Medical researchers and scientists believe that stem cell therapy will, in the near future, advance medicine dramatically and change the course of disease treatment. This is because stem cells have the ability to grow into any kind of cell and, if transplanted into the body, will relocate to the damaged tissue, replacing it. For example, neural cells in the spinal cord, brain, optic nerves, or other parts of the central nervous system that have been injured can be replaced by injected stem cells. Various stem cell therapies are already practiced, a popular one being bone marrow transplants that are used to treat leukemia. In theory and in fact, lifeless cells anywhere in the body, no matter what the cause of the disease or injury, can be replaced with vigorous new cells because of the remarkable plasticity of stem cells. Biomed companies predict that with all of the research activity in stem cell therapy currently being directed toward the technology, a wider range of disease types including cancer, diabetes, spinal cord injury, and even multiple sclerosis will be effectively treated in the future. Recently announced trials are now underway to study both safety and efficacy of autologous stem cell transplantation in MS patients because of promising early results from previous trials.
History
Research into stem cells grew out of the findings of two Canadian researchers, Dr’s James Till and Ernest McCulloch at the University of Toronto in 1961. They were the first to publish their experimental results into the existence of stem cells in a scientific journal. Till and McCulloch documented the way in which embryonic stem cells differentiate themselves to become mature cell tissue. Their discovery opened the door for others to develop the first medical use of stem cells in bone marrow transplantation for leukemia. Over the next 50 years their early work has led to our current state of medical practice where modern science believes that new treatments for chronic diseases including MS, diabetes, spinal cord injuries and many more disease conditions are just around the corner.
There are a number of sources of stem cells, namely, adult cells generally extracted from bone marrow, cord cells, extracted during pregnancy and cryogenically stored, and embryonic cells, extracted from an embryo before the cells start to differentiate. As to source and method of acquiring stem cells, harvesting autologous adult cells entails the least risk and controversy. 
Autologous stem cells are obtained from the patient’s own body; and since they are the patient’s own, autologous cells are better than both cord and embryonic sources as they perfectly match the patient’s own DNA, meaning that they will never be rejected by the patient’s immune system. Autologous transplantation is now happening therapeutically at several major sites world-wide and more studies on both safety and efficacy are finally being announced. With so many unrealized expectations of stem cell therapy, results to date have been both significant and hopeful, if taking longer than anticipated.
What’s been the Holdup?
Up until recently, there have been intense ethical debates about stem cells and even the studies that researchers have been allowed to do. This is because research methodology was primarily concerned with embryonic stem cells, which until recently required an aborted fetus as a source of stem cells. The topic became very much a moral dilemma and research was held up for many years in the US and Canada while political debates turned into restrictive legislation. Other countries were not as inflexible and many important research studies have been taking place elsewhere. Thankfully embryonic stem cells no longer have to be used as much more advanced and preferred methods have superseded the older technologies. While the length of time that promising research has been on hold has led many to wonder if stem cell therapy will ever be a reality for many disease types, the disputes have led to a number of important improvements in the medical technology that in the end, have satisfied both sides of the ethical issue.
CCSVI Clinic
CCSVI Clinic has been on the leading edge of MS treatment for the past several years. We are the only group facilitating the treatment of MS patients requiring a 10-day patient aftercare protocol following neck venous angioplasty that includes daily ultrasonography and other significant therapeutic features for the period including follow-up surgeries if indicated. There is a strict safety protocol, the results of which are the subject of an approved IRB study. The goal is to derive best practice standards from the data. With the addition of ASC transplantation, our research group has now preparing application for member status in International Cellular Medicine Society (ICMS), the globally-active non-profit organization dedicated to the improvement of cell-based medical therapies through education of physicians and researchers, patient safety, and creating universal standards. For more information please visit http://www.theprofitron.com/bic/